Samia Mora

List of Publications by Year
in descending order

211 papers	28,149 citations	14614 66 h-index	5663 162 g-index
216 all docs	216 docs citations	216 times ranked	31762 citing authors

#	Article	IF	Citations
1	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 2008, 359, 2195-2207.	13.9	5,712
2	Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013, 45, 1274-1283.	9.4	2,641
3	Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women. JAMA - Journal of the American Medical Association, 2007, 298, 309.	3.8	1,326
4	Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine, 2019, 380, 33-44.	13.9	1,141
5	Physical Activity and Reduced Risk of Cardiovascular Events. Circulation, 2007, 116, 2110-2118.	1.6	799
6	Common variants associated with plasma triglycerides and risk for coronary artery disease. Nature Genetics, 2013, 45, 1345-1352.	9.4	754
7	Marine nâˆ’3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. New England Journal of Medicine, 2019, 380, 23-32.	13.9	684
8	Association of LDL Cholesterol, Nonâ€“HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. JAMA - Journal of the American Medical Association, 2012, 307, 1302.	3.8	650
9	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-pointsâ€”a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 2016, 37, 1944-1958.	1.0	542
10	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. Journal of the American College of Cardiology, 2014, 64, 485-494.	1.2	512
11	Ability of Exercise Testing to Predict Cardiovascular and All-Cause Death in Asymptomatic Women. JAMA - Journal of the American Medical Association, 2003, 290, 1600-7.	3.8	472
12	Physical Activity Attenuates the Influence of FTO Variants on Obesity Risk: A Meta-Analysis of 218,166 Adults and 19,268 Children. PLoS Medicine, 2011, 8, e1001116.	3.9	446
13	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science, 2016, 351, 1166-1171.	6.0	438
14	Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women. Circulation, 2009, 119, 931-939.	1.6	427
15	Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events. Circulation, 2008, 118, 993-1001.	1.6	366
16	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet, The, 2018, 392, 1311-1320.	6.3	355
17	Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk. Circulation, 2014, 129, 635-642.	1.6	338
18	Association of Physical Activity and Body Mass Index With Novel and Traditional Cardiovascular Biomarkers in Women. JAMA - Journal of the American Medical Association, 2006, 295, 1412.	3.8	331

#	Article	IF	Citations
19	High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events. Journal of the American College of Cardiology, 2012, 60, 508-516.	1.2	325
20	A Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians. PLoS ONE, 2015, 10, e0120758.	1.1	323
21	LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2007, 192, 211-217.	0.4	322
22	Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. Journal of Clinical Lipidology, 2011, 5, 105-113.	0.6	311
23	Forty-Three Loci Associated with Plasma Lipoprotein Size, Concentration, and Cholesterol Content in Genome-Wide Analysis. PLoS Genetics, 2009, 5, e1000730.	1.5	300
24	Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia. Circulation, 2010, 121, 1069-1077.	1.6	287
25	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet, The, 2010, 376, 333-339.	6.3	221
26	High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy. Circulation, 2013, 128, 1189-1197.	1.6	203
27	Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events. Circulation, 2014, 129, 553-561.	1.6	189
28	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry, 2018, 64, 1006-1033.	1.5	189
29	Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)â€"Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?. American Journal of Cardiology, 2006, 97, 33-41.	0.7	182
30	Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. European Heart Journal, 2016, 37, 1373-1379.	1.0	180
31	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. Circulation, 2017, 135, 2494-2504.	1.6	180
32	A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events. Journal of the American Heart Association, 2014, 3, e001221.	1.6	179
33	Lipoprotein(a) and Risk of Type 2 Diabetes. Clinical Chemistry, 2010, 56, 1252-1260.	1.5	165
34	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. Circulation, 2013, 128, 1504-1512.	1.6	162
35	Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women. Diabetes, 2010, 59, 1153-1160.	0.3	157
36	Blood pressure and risk of developing type 2 diabetes mellitus: The Women's Health Study. European Heart Journal, 2007, 28, 2937-2943.	1.0	153

#	Article	IF	Citations
37	Comparison of LDL Cholesterol Concentrations by Friedewald Calculation and Direct Measurement in Relation to Cardiovascular Events in 27 331 Women. Clinical Chemistry, 2009, 55, 888-894.	1.5	153
38	Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy. Circulation, 2012, 125, 1979-1987.	1.6	149
39	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpointsâ€"A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry, 2016, 62, 930-946.	1.5	145
40	Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. Circulation Genomic and Precision Medicine, 2018, 11, e002157.	1.6	145
41	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis, 2020, 294, 46-61.	0.4	137
42	Exercise Blood Pressure and Future Cardiovascular Death in Asymptomatic Individuals. Circulation, 2010, 121, 2109-2116.	1.6	130
43	The use of high-sensitivity assays for C-reactive protein in clinical practice. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 621-635.	3.3	123
44	Lipoprotein Particles and Incident Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis. Diabetes Care, 2015, 38, 628-636.	4.3	120
45	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clinical Chemistry and Laboratory Medicine, 2020, 58, 496-517.	1.4	119
46	Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality. Circulation, 2014, 130, 546-553.	1.6	118
47	AHA/ACCF 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. Circulation, 2009, 120, 1296-1336.	1.6	117
48	Lipid biomarkers and long-term risk of cancer in the Womenâ€™s Health Study. American Journal of Clinical Nutrition, 2016, 103, 1397-1407.	2.2	117
49	Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1544-1550.	1.1	105
50	Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo. Circulation, 2015, 132, 2220-2229.	1.6	101
51	Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Lowâ€Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2017, 6, .	1.6	98
52	Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence. Circulation, 2018, 138, 2330-2341.	1.6	98
53	Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circulation Research, 2016, 118, 1106-1115.	2.0	97
54	The Metabolic Syndrome in Women. Cardiology in Review, 2006, 14, 286-291.	0.6	96

#	Article	IF	Citations
55	Enhanced Risk Assessment in Asymptomatic Individuals With Exercise Testing and Framingham Risk Scores. Circulation, 2005, 112, 1566-1572.	1.6	90
56	On-Treatment Nonâ€“High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy. Journal of the American College of Cardiology, 2012, 59, 1521-1528.	1.2	90
57	The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines. Clinical Chemistry, 2009, 55, 219-228.	1.5	86
58	Lifestyle Interaction With Fat Mass and Obesity-Associated (FTO) Genotype and Risk of Obesity in Apparently Healthy U.S. Women. Diabetes Care, 2011, 34, 675-680.	4.3	84
59	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiology, 2021, 6, 437.	3.0	82
60	ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. Journal of the American College of Cardiology, 2009, 54, 1364-1405.	1.2	80
61	Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 976-982.	1.1	79
62	Interaction of Body Mass Index and Framingham Risk Score in Predicting Incident Coronary Disease in Families. Circulation, 2005, 111, 1871-1876.	1.6	77
63	Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use. Circulation, 2009, 119, 2396-2404.	1.6	77
64	Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events. Circulation, 2006, 114, 381-387.	1.6	76
65	Paradoxical Association of Lipoprotein Measures With Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 612-619.	2.1	75
66	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. Clinical Chemistry, 2017, 63, 870-879.	1.5	74
67	Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. Journal of the American College of Cardiology, 2018, 72, 287-296.	1.2	73
68	Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2021, 325, 1061.	3.8	73
69	Managing Atherosclerotic Cardiovascular Risk in Young Adults. Journal of the American College of Cardiology, 2022, 79, 819-836.	1.2	72
70	Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1490-1500.	2.2	71
71	Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegAâ€3 TriaL (VITAL). Journal of Bone and Mineral Research, 2020, 35, 883-893.	3.1	69
72	Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet. JAMA Network Open, 2018, 1, e185708.	2.8	65

#	Article	IF	Citations
73	Dietary Intakes and Circulating Concentrations of Branched-Chain Amino Acids in Relation to Incident Type 2 Diabetes Risk Among High-Risk Women with a History of Gestational Diabetes Mellitus. Clinical Chemistry, 2018, 64, 1203-1210.	1.5	64
74	Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation. JAMA Cardiology, 2019, 4, 144.	3.0	64
75	Directed Non-targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids and Related Oxylipins. Cell Chemical Biology, 2019, 26, 433-442.e4.	2.5	64
76	Homocysteine, 5,10-Methylenetetrahydrofolate Reductase 677C>T Polymorphism, Nutrient Intake, and Incident Cardiovascular Disease in 24 968 Initially Healthy Women. Clinical Chemistry, 2007, 53, 845-851.	1.5	62
77	Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Veryâ€Lowâ€Density Lipoproteins. Journal of the American Heart Association, 2017, 6, .	1.6	61
78	Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment. Thyroid, 2019, 29, 760-777.	2.4	61
79	Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease. JAMA Internal Medicine, 2016, 176, 1195.	2.6	58
80	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Womenâ€™s Health Initiative. JAMA Internal Medicine, 2018, 178, 1231.	2.6	58
81	High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 55-63.	0.9	56
82	Statistical Workflow for Feature Selection in Human Metabolomics Data. Metabolites, 2019, 9, 143.	1.3	55
83	Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemiaâ€”a randomized controlled feeding trial. American Journal of Clinical Nutrition, 2022, 115, 154-162.	2.2	55
84	Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30Âmg/dl) With Rosuvastatin 20Âmg Daily (from JUPITER). American Journal of Cardiology, 2014, 114, 1682-1689.	0.7	53
85	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. Clinical Chemistry, 2015, 61, 1156-1163.	1.5	53
86	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 136.	3.0	53
87	Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels. Annals of Internal Medicine, 2011, 155, 742.	2.0	52
88	The Fat-Mass and Obesity-Associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. American Heart Journal, 2010, 160, 1163-1169.	1.2	51
89	Thyroid and Cardiovascular Disease. Circulation, 2019, 139, 2892-2909.	1.6	51
90	A Comparison of the Theoretical Relationship between HDL Size and the Ratio of HDL Cholesterol to Apolipoprotein A-I with Experimental Results from the Women's Health Study. Clinical Chemistry, 2013, 59, 949-958.	1.5	48

#	Article	IF	Citations
91	Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trialâ€“Lipid Lowering Arm. JAMA Internal Medicine, 2019, 179, 898.	2.6	46
92	Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence. Circulation Research, 2020, 126, 112-128.	2.0	45
93	Circulating Nâ€Linked Glycoprotein Sideâ€Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. Journal of the American Heart Association, 2016, 5, .	1.6	44
94	Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). American Journal of Cardiology, 2016, 117, 1921-1927.	0.7	43
95	Lipoprotein Subclass Abnormalities and Incident Hypertension in Initially Healthy Women. Clinical Chemistry, 2011, 57, 1178-1187.	1.5	42
96	Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization. Circulation, 2020, 141, 784-786.	1.6	41
97	Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20Âyears: The Women's Health Study. Journal of Clinical Lipidology, 2017, 11, 1257-1267.e2.	0.6	40
98	Markers of Inflammation and Incident Breast Cancer Risk in the Womenâ€™s Health Study. American Journal of Epidemiology, 2018, 187, 705-716.	1.6	40
99	Nonfasting for Routine Lipid Testing. JAMA Internal Medicine, 2016, 176, 1005.	2.6	38
100	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Current Vascular Pharmacology, 2019, 17, 498-514.	0.8	38
101	Altered branched chain amino acid metabolism. Current Opinion in Cardiology, 2018, 33, 558-564.	0.8	34
102	Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2016, 316, 709.	3.8	33
103	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. PLoS ONE, 2016, 11, e0165615.	1.1	31
104	Association of the Mediterranean Diet With Onset of Diabetes in the Womenâ€™s Health Study. JAMA Network Open, 2020, 3, e2025466.	2.8	28
105	Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL). American Journal of Cardiology, 2014, 113, 1378-1382.	0.7	27
106	GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. Aids, 2019, 33, 547-557.	1.0	27
107	Hypothyroidism and Kidney Function: A Mendelian Randomization Study. Thyroid, 2020, 30, 365-379.	2.4	27
108	Concordance of Cardiovascular Risk Factors and Behaviors in a Multiethnic US Nationwide Cohort of Married Couples and Domestic Partners. JAMA Network Open, 2020, 3, e2022119.	2.8	26

#	Article	IF	Citations
109	Group IIA Secretory Phospholipase A ₂ , Vascular Inflammation, and Incident Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1182-1190.	1.1	25
110	Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment. Contemporary Clinical Trials, 2019, 87, 105854.	0.8	24
111	Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multiâ€Ethnic Study of Atherosclerosis. Clinical Cardiology, 2018, 41, 1439-1445.	0.7	23
112	Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clinical Chemistry, 2019, 65, 1508-1521.	1.5	23
113	The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2019, 282, 91-99.	0.4	23
114	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. Current Vascular Pharmacology, 2019, 17, 538-540.	0.8	23
115	Fasting for Lipid Testing: Is It Worth the Trouble?. Archives of Internal Medicine, 2012, 172, 1710.	4.3	22
116	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. Clinical Chemistry, 2016, 62, 428-435.	1.5	22
117	Circulating branched-chain amino acids and long-term risk of obesity-related cancers in women. Scientific Reports, 2020, 10, 16534.	1.6	22
118	A National Interactive Web-Based Physical Activity Intervention in Women, Evaluation of the American Heart Association Choose to Move Program 2006â€“2007. American Journal of Cardiology, 2012, 109, 1754-1760.	0.7	21
119	Antiâ€Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016507.	1.6	21
120	Red blood cell fatty acid patterns from 7 countries: Focus on the Omega-3 index. Prostaglandins Leukotrienes and Essential Fatty Acids, 2022, 179, 102418.	1.0	21
121	Effects of statins on the immunoglobulin G glycome. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1152-1158.	1.1	20
122	Exercise-Induced Ventricular Ectopy andÂCardiovascular Mortality in Asymptomatic Individuals. Journal of the American College of Cardiology, 2021, 78, 2267-2277.	1.2	20
123	The Guidelines Battle on Starting Statins. New England Journal of Medicine, 2014, 370, 1652-1658.	13.9	19
124	SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19. Scientific Reports, 2021, 11, 4945.	1.6	19
125	Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. Circulation Genomic and Precision Medicine, 2021, 14, e003330.	1.6	19
126	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. Current Vascular Pharmacology, 2019, 17, 515-537.	0.8	19

#	Article	IF	Citations
127	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. European Journal of Preventive Cardiology, 2014, 21, 866-875.	0.8	18
128	Effects of Vitamin D3 Supplementation on Body Composition in the VITamin D and OmegA-3 TriaL (VITAL). Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1377-1388.	1.8	18
129	Risk Factors for Premature Myocardial Infarction: A Systematic Review and Meta-analysis of 77 Studies. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 783-794.	1.2	18
130	Glycosylation Signatures of Inflammation Identify Cardiovascular Risk. Circulation Research, 2016, 119, 1154-1156.	2.0	17
131	GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis. Angiology, 2019, 70, 737-746.	0.8	17
132	Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL. Journal of Clinical Lipidology, 2020, 14, 241-251.	0.6	17
133	Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1501-1510.	2.2	17
134	Gender-Specific Prediction of Cardiac Disease. Cardiology in Review, 2006, 14, 281-285.	0.6	16
135	Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women. Journal of the Endocrine Society, 2017, 1, 113-123.	0.1	16
136	Re-assessing the role of non-fasting lipids; a change in perspective. Annals of Translational Medicine, 2016, 4, 431-431.	0.7	16
137	Premature Myocardial Infarction in the Middle East and North Africa: Rationale for the Gulf PREVENT Study. Angiology, 2020, 71, 17-26.	0.8	14
138	Habitual Fish Consumption, nâ€3 Fatty Acids, and Nuclear Magnetic Resonance Lipoprotein Subfractions in Women. Journal of the American Heart Association, 2020, 9, e014963.	1.6	14
139	Association of Highâ€Density Lipoproteinâ€Cholesterol Versus Apolipoprotein Aâ€I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancerâ€Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. Journal of the American Heart Association, 2017, 6, .	1.6	13
140	One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL). Metabolites, 2020, 10, 431.	1.3	13
141	Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study. Thyroid, 2021, 31, 1305-1315.	2.4	13
142	Genetic associations with lipoprotein subfraction measures differ by ethnicity in the multi-ethnic study of atherosclerosis (MESA). Human Genetics, 2017, 136, 715-726.	1.8	12
143	The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering. Circulation, 2018, 137, 20-23.	1.6	12
144	Quantum approximate Bayesian computation for NMR model inference. Nature Machine Intelligence, 2020, 2, 396-402.	8.3	12

#	Article	IF	Citations
145	Branched-Chain Amino Acids and Risk of Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkab059.	1.4	12
146	Aspirin Therapy in Primary Prevention. Archives of Internal Medicine, 2012, 172, 217.	4.3	11
147	Risk factors associated with premature myocardial infarction: a systematic review protocol. BMJ Open, 2019, 9, e023647.	0.8	11
148	Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study. Clinical Chemistry, 2018, 64, 231-241.	1.5	10
149	Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Womenâ€™s Genome Health Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 97-106.	1.1	10
150	Providing Patients With Global Cardiovascular Risk Information. Archives of Internal Medicine, 2010, 170, 227.	4.3	9
151	Association of Highâ€Density Lipoprotein Particles and Highâ€Density Lipoprotein Apolipoprotein Câ€III Content With Cardiovascular Disease Risk According to Kidney Function: The Multiâ€Ethnic Study of Atherosclerosis. Journal of the American Heart Association, 2019, 8, e013713.	1.6	9
152	Glycosylation and Cardiovascular Diseases. Advances in Experimental Medicine and Biology, 2021, 1325, 307-319.	0.8	9
153	What's Different about Women's Health?. Clinical Chemistry, 2014, 60, 1-3.	1.5	8
154	Cholesterol Insights and Controversies From the UK Biobank Study. Circulation, 2019, 140, 553-555.	1.6	8
155	Fasting status and metabolic health in relation to plasma branched chain amino acid concentrations in women. Metabolism: Clinical and Experimental, 2021, 117, 154391.	1.5	8
156	Association of obesity indices with in-hospital and 1-year mortality following acute coronary syndrome. International Journal of Obesity, 2021, 45, 358-368.	1.6	8
157	Sugar-Sweetened Beverage Consumption May Modify Associations Between Genetic Variants in the CHREBP (Carbohydrate Responsive Element Binding Protein) Locus and HDL-C (High-Density Lipoprotein) Tj ETQq1 1 0.784314 rgBT / e003288.	1.6	8
158	Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of HeartÂFailure Hospitalization. JACC: Heart Failure, 2022, 10, 227-234.	1.9	8
159	Nonfasting Lipids for All Patients?. Clinical Chemistry, 2021, 67, 41-45.	1.5	7
160	Marine Omega-3 Fatty Acids and Cardiovascular Disease Prevention: Seeking Clearer Water. Mayo Clinic Proceedings, 2021, 96, 277-279.	1.4	7
161	Lifelong low Lp(a) levels: genetics give a green light?. European Heart Journal, 2021, 42, 1157-1159.	1.0	7
162	Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions. Neurology, 2021, 97, e2223-e2235.	1.5	7

#	Article	IF	Citations
163	Mediterranean Diet Social Network Impact along 11 Years in the Major US Media Outlets: Thematic and Quantitative Analysis Using Twitter. International Journal of Environmental Research and Public Health, 2022, 19, 784.	1.2	7
164	Coronary artery disease in postmenopausal women. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 67-79.	0.4	6
165	Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease. Diabetes Research and Clinical Practice, 2006, 74, 267-273.	1.1	6
166	Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imaging. European Heart Journal, 2013, 34, 2074-2082.	1.0	6
167	Are There Sex Differences in Acute Coronary Syndrome Presentation?. JAMA Internal Medicine, 2013, 173, 1861.	2.6	6
168	Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoproteinâ€“Related Measures. Circulation: Cardiovascular Genetics, 2015, 8, 688-695.	5.1	6
169	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): An Overlooked Form of Hypoglycemia in Clinical Practice. International Journal of Endocrinology, 2018, 2018, 1-6.	0.6	6
170	Is it time to abandon fasting for routine lipid testing?. Cleveland Clinic Journal of Medicine, 2017, 84, 919-922.	0.6	6
171	Association of Modifiable Lifestyle Factors with Plasma Branched-Chain Amino Acid Metabolites in Women. Journal of Nutrition, 2022, 152, 1515-1524.	1.3	6
172	Aspirin Therapy in Women. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 63-64.	0.9	5
173	Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. Current Atherosclerosis Reports, 2018, 20, 15.	2.0	5
174	Fasting for Laboratory Tests Poses a High Risk of Hypoglycemia in Patients with Diabetes: A Pilot Prevalence Study in Clinical Practice. International Journal of Clinical Medicine, 2016, 07, 653-667.	0.1	5
175	Response to Letter Regarding Article, â€œFasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Eventsâ€, Circulation, 2009, 119, .	1.6	4
176	Response to Letter Regarding Article, â€œLipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 21	1.6	4
177	Probabilistic identification of saccharide moieties in biomolecules and their protein complexes. Scientific Data, 2020, 7, 210.	2.4	4
178	Misperceptions and management of risk: Ongoing challenges in women's cardiovascular health. Atherosclerosis, 2021, 324, 109-111.	0.4	4
179	Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 525-537.	1.8	4
180	Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease. JAMA Internal Medicine, 2022, 182, 587.	2.6	4

#	Article	IF	Citations
181	Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy. Journal of the American Heart Association, 2018, 7, .	1.6	3
182	Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL. Clinical Chemistry, 2019, 65, 1487-1492.	1.5	3
183	Lp(a)â€™s Odyssey. Journal of the American College of Cardiology, 2020, 75, 145-147.	1.2	3
184	Biphasic Pulmonary Regurgitation. Echocardiography, 2009, 26, 720-723.	0.3	2
185	Moving Beyond Mean Glycemia: 1,5-Anhydroglucitol and Microvascular Complications of Diabetes. Clinical Chemistry, 2014, 60, 1359-1361.	1.5	2
186	Fibroblast growth factor-21 levels in metabolic syndrome: Another instrument in a widening tool belt?. Atherosclerosis, 2019, 281, 143-144.	0.4	2
187	Certain cardiac risk factors predict risk factor interventions and influence communication between physicians and patients. American Journal of Cardiology, 2000, 86, 783-785.	0.7	1
188	Response to Letter Regarding Article, â€œLipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Womenâ€• Circulation, 2009, 120, .	1.6	1
189	Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels. Evidence-Based Medicine, 2012, 17, 133-134.	0.6	1
190	Reply to Letters Regarding Article, â€œPrognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)â€• Circulation, 2015, 131, e473.	1.6	1
191	Predicting Asthma Exacerbations from a Drop of Blood. Clinical Chemistry, 2017, 63, 799-801.	1.5	1
192	Effects of a Low-Carbohydrate Diet on Cardiometabolic Risk Factors During Weight-Loss Maintenance: A Randomized Controlled Feeding Trial. Current Developments in Nutrition, 2020, 4, nzaa049_018.	0.1	1
193	Abstract 019: Modifiable Lifestyle Factors And Plasma Branched Chain Amino Acids: An Analysis Of N=19,472 US Women. Circulation, 2021, 143, .	1.6	1
194	Assessing the dyslipidemias: to fast or not to fast?. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 97-103.	1.2	1
195	Abstract 13479: Association of Plasma Branched Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. Circulation, 2020, 142, .	1.6	1
196	Exercise Treadmill Stress Testing With and Without Imaging. , 2011, , 489-502.		1
197	1102â€…Fish oil supplementation and pro-inflammatory and pro-resolving lipid mediators in patients with and without systemic lupus erythematosus. , 2021, , .		1
198	The association of cardiovascular mortality with a first-degree family member history of different cardiovascular diseases. Journal of Geriatric Cardiology, 2021, 18, 816-824.	0.2	1

#	Article	IF	Citations
199	The Curious Case of Synergy between Lipoprotein (a), Coronary Calcification, and Cardiovascular Disease Risk. Clinical Chemistry, 2022, 68, 1235-1237.	1.5	1
200	Use of High-Sensitivity C-Reactive Protein for Risk Assessment. , 2009, , 158-166.		0
201	Response to Letters Regarding Article, â€œStatins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women from Primary Prevention Trialsâ€• Circulation, 2010, 122, .	1.6	0
202	Response to Letter Regarding Article, â€œHigh-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapyâ€• Circulation, 2014, 129, e481.	1.6	0
203	Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Diseaseâ€”Reply. JAMA - Journal of the American Medical Association, 2016, 316, 2276.	3.8	0
204	Risk and Benefit Information and Use of Aspirinâ€”Reply. JAMA Internal Medicine, 2017, 177, 291.	2.6	0
205	Partitioning the Genetic Architecture of Plasma Lipoprotein(a) and Kringle IV Type 2 Repeats: Implications for Therapeutic Lowering. Clinical Chemistry, 2017, 63, 1792-1794.	1.5	0
206	A little more time around the track may go a long way: Implications of increasing moderate to vigorous physical activity in pre-adolescents. Atherosclerosis, 2019, 288, 160-162.	0.4	0
207	A Still-Ignored Cardiovascular Risk Factorâ€”A History of Preeclampsiaâ€”Reply. JAMA Cardiology, 2021, 6, 1098.	3.0	0
208	Mediterranean diet social network impact along 11 years in the major US media outlets: Thematic and Quantitative Analysis using Twitter. (Preprint). JMIR Public Health and Surveillance, 0, , .	1.2	0
209	Abstract 16278: Discordant Lipid Phenotype and Other Determinants of Statin Response in the Pravastatin Inflammation/crp Evaluation (PRINCE) Trial. Circulation, 2020, 142, .	1.6	0
210	Abstract 11848: Biomarkers of Glucose-Insulin Homeostasis, Randomized Treatment With Omega-3 and Vitamin D Supplementation, and Incident Type 2 Diabetes: Prospective Analysis From the Vitamin D and Omega-3 Trial (VITAL). Circulation, 2021, 144, .	1.6	0
211	Abstract 12860: Effects of Marine Omega-3 and Vitamin D Supplementation on Circulating Biomarkers of Glucose-Insulin Homeostasis and Incident Cardiovascular Disease in the Vitamin D and Omega-3 Trial (VITAL). Circulation, 2021, 144, .	1.6	0